What is ENDRA Life Sciences?
Founded in 2009 and headquartered in Ann Arbor, Michigan, ENDRA Life Sciences operates at the intersection of advanced medical imaging and clinical diagnostics. The company is primarily focused on the development of non-invasive technologies designed for the early detection and monitoring of liver disease. By leveraging sophisticated acoustic and light-based imaging modalities, ENDRA aims to provide clinicians with actionable data that can mitigate the need for invasive biopsies. As the company transitions through its current lifecycle stage, it is increasingly focused on scaling its commercial infrastructure and navigating the complex regulatory pathways required for widespread clinical adoption in the global healthcare market.
How much funding has ENDRA Life Sciences raised?
ENDRA Life Sciences has raised a total of $27.9M across 4 funding rounds:
Stock Offering
$8.4M
Debt
$150K
Private Equity
$4.9M
Stock/Share Issuance
$14.4M
Stock Issuance/Offering (2017): $8.4M, investors not publicly disclosed
Debt (2020): $150K led by PPP
Private Equity (2025): $4.9M, investors not publicly disclosed
Stock/Share Issuance (2025): $14.4M, investors not publicly disclosed
Key Investors in ENDRA Life Sciences
Undisclosed Investor
An undisclosed institutional entity participating in the latest round of private equity and share issuance to support long-term clinical development.
PPP
Public-Private Partnership
Market Participants
A collective of public and private market participants contributing to the company's ongoing stock issuance and capital structure optimization.
What's next for ENDRA Life Sciences?
With the recent infusion of capital, ENDRA Life Sciences is well-positioned to accelerate its research and development initiatives and expand its commercial footprint. The strategic roadmap likely involves intensifying clinical validation studies to support broader regulatory clearances and enhancing its go-to-market strategy for its flagship diagnostic platforms. As the company moves forward, the focus will remain on achieving operational milestones that demonstrate the clinical utility and economic value of its technology to healthcare providers and payers alike. This phase of growth is critical for establishing long-term sustainability and market leadership in the competitive landscape of diagnostic life sciences.
See full ENDRA Life Sciences company page
